Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Japan.
J Radiat Res. 2010;51(4):481-4. doi: 10.1269/jrr.09134. Epub 2010 Jun 30.
In this study, we evaluated the feasibility, efficacy and toxicity of concurrent chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium) for T2N0 glottic carcinoma. A total of 23 patients with T2N0 glottic carcinoma received chemoradiotherapy with S-1. Radiotherapy consisted of five daily fractions of 2 Gy per week, to a total median dose of 70 Gy. S-1 was administered 65 mg/m(2) per day for 4 weeks, beginning on the day therapy was started, followed by 2 weeks off the drug and twice a day until the end of radiotherapy. Initial local control rate of the primary tumor was achieved in all patients. The median follow-up period for all patients was 38 months. The 3-year local control rate was 95.4%. Regarding adverse reactions, grade 3 mucositis upon clinical examination, mucositis upon functional/symptomatic examination, dysphagia, hepatic toxicity and anemia were observed in 13, 2, 2, 1 and 1 patients, respectively. This chemoradiotherapy did not result in grade 4 acute toxicity or severe late toxicity. Chemoradiotherapy with S-1 was feasible, well tolerated and effective. This therapy is suggested as a possible regimen for improving local control of T2N0 glottic carcinoma.
在这项研究中，我们评估了同步放化疗联合替吉奥（替加氟、吉美嘧啶、奥替拉西钾）治疗 T2N0 声门型喉癌的可行性、疗效和毒性。共 23 例 T2N0 声门型喉癌患者接受了同步放化疗联合替吉奥。放疗采用每周 5 次，每次 2 Gy，总中位数剂量为 70 Gy。替吉奥的剂量为 65mg/m2，每天一次，连用 4 周，在开始治疗的当天开始，然后停药 2 周，每天两次，直到放疗结束。所有患者的原发肿瘤初始局部控制率均达到。所有患者的中位随访时间为 38 个月。3 年局部控制率为 95.4%。关于不良反应，13 例患者出现 3 级临床检查可见的黏膜炎、2 例患者出现 2 级功能/症状检查可见的黏膜炎、2 例患者出现吞咽困难、1 例患者出现肝毒性、1 例患者出现贫血。这种化疗联合放疗没有导致 4 级急性毒性或严重晚期毒性。替吉奥同步放化疗是可行的，耐受性良好且有效。这种治疗方法被建议作为提高 T2N0 声门型喉癌局部控制率的可能方案。
